Study of REGN7945 plus linvoseltamab for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new combination of two drugs (REGN7945 and linvoseltamab) for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if the combination is safe and effective, and it may offer a new option if other therapies have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have tried at least 3 different types of treatment for your multiple myeloma, including a drug that targets CD38, an immunomodulatory drug (like lenalidomide or pomalidomide), and a proteasome inhibitor (like bortezomib or carfilzomib).
- You are able to get around and take care of yourself (able to do light work or be fully active).
- Your cancer can be measured with standard tests (like blood or urine tests, or scans).
- Your blood counts, liver, and kidney function are good enough based on blood tests.
- You do not have certain other conditions like plasma cell leukemia, amyloidosis, or active brain involvement from your myeloma.
- You have not had a stem cell transplant within the last 12 weeks (autologous) or 6 months (allogeneic), and you have not had certain cancer treatments or vaccines within the last few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LBL-034 in people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if it is safe and effective.
This trial tests whether REGN17372 plus linvoseltamab is safe for people with multiple myeloma that has come back or not responded to prior treatments. You may join if you have tried at least 3 other therapies.
This trial tests linvoseltamab, an experimental antibody medicine, in adults whose multiple myeloma has come back or does not respond to treatment. It may help some people by targeting myeloma cells after multiple prior therapies have failed.
This trial tests adding a new drug, linvoseltamab, to the standard maintenance therapy lenalidomide for people with newly diagnosed multiple myeloma. The goal is to see if it can deepen responses or turn a relapse back to a negative minimal residual disease (MRD) state, where no cancer cells are detectable.
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.